Introduction
First-line treatment of patients with anaplastic glioma and glioblastoma, also referred to as high-grade gliomas, has been largely standardized and includes radiation therapy (RT) and the alkylating agent temozolomide (TMZ). Whether these treatment modalities are used in a combined approach or rather sequentially depends on the WHO grade, age, and molecular markers such as the methylation status of the O 6 -methylguanine DNA methyltransferase (MGMT) gene promoter [1] [2] [3] . In contrast, treatment is much less standardized when the tumor recurs [4] . The antiangiogenic agent bevacizumab has been approved for recurrent glioblastoma in the US but not in most European countries [5] . Other treatment options that are frequently used include reresection [6] , the administration of nitrosoureas such as lomustine [7] [8] [9] [10] , rechallenge with TMZ [11] , and numerous experimental drugs [12] . In general, these treatment options show limited activity. The situation is particularly challenging in patients suffering from repeated relapses who present with sustained good performance status seeking further therapy. Here we report our institutional experience with the combination of carboplatin and etoposide in heavily pretreated patients with malignant gliomas at a third or fourth tumor progression.
Patients and Methods
We retrospectively reviewed tumor board proceedings from 2010-2013 and identified 12 patients with recurrent high-grade glioma treated with carboplatin (240 mg/m 2 on day 1) and etoposide (100 mg/m 2 on days 2 and 3) every 4 weeks following multiple prior therapies. All patients had magnetic resonance imaging (MRI) every 8-12 weeks or in the case of clinical deterioration. MRI was evaluated according to Response Assessment in Neuro-Oncology (RANO) criteria [13] . Progression-free survival (PFS) was determined from the date of treatment start with salvage carboplatin and etoposide therapy until the date of further progression according to the Kaplan-Meier method. Overall survival (OS) was calculated from the initiation of carboplatin and etoposide treatment until death. The total OS was determined from the date of the initial surgery to death.
Results
Of the 12 patients, 8 had been diagnosed with glioblastoma, 3 with anaplastic astrocytoma, and 1 with anaplastic oligodendroglioma. All patients had a third or fourth tumor recurrence when treatment with carboplatin/etoposide was initiated. The median age at diagnosis was 50 years (range 37-68), with a preponderance of males (8 males and 4 women). Following the initial surgery, further therapy lines consisted of RT alone (n = 3, anaplastic astrocytoma), RT with concomitant and adjuvant chemotherapy with TMZ (n = 7, glioblastoma), and RT in combination with temsirolimus (n = 1, EORTC 26082, NCT01019434, glioblastoma). One patient received no adjuvant therapy following surgery because of the initial diagnosis of a WHO grade II oligodendroglioma. Upon progression to an anaplastic glioma after 22 months, reresection was performed with subsequent RT. In the other patients, second-line therapy comprised reresection followed by RT, reexposure to TMZ, or bevacizumab in combination with ornatuzumab/placebo (Genentech GO27819, NCT01632228). Patients not undergoing reresection (n = 7) received TMZ or bevacizumab alone or in combination with RO5323441 [14] . Depending on pretreatment, third-and fourth-line therapy consisted of TMZ, lomustine, bevacizumab alone, or bevacizumab in combination with TMZ or lomustine. Carboplatin in combination with etoposide was administered as fourthline therapy in 3 patients and as fifth-line therapy in 9.
Detailed patient characteristics are summarized in table 1 . At the time of initiation of carboplatin and etoposide, most patients presented in good overall condition with a median Karnofsky performance status (KPS) of 80% and only 4 out of 12 patients requiring steroid administration. Treatment with carboplatin and etoposide was only moderately tolerated and CTCAE grade 3 and 4 hematotoxicity occurred in 67% of the patients. Four patients received granulocyte colony-stimulating factor treatment and antibiotic prophylaxis for prolonged neutropenia.
The median PFS of patients receiving etoposide-based salvage therapy was 2.5 months. We did not record any complete or partial responses and the PFS at 6 months was 0%. The median OS after initiation of carboplatin/ etoposide was 3.3 months ( fig. 1 ) . The median OS from the initial diagnosis was 21.7 months.
Discussion
There is no standard of care for patients with recurrent high-grade gliomas. Various drugs and regimens have been examined but no standard has been established so [15] . Patients who experience repeated tumor progression may present with a reduced KPS which does not allow for further tumor-specific therapy but rather requires a change to best supportive care. However, a considerable number of patients still have a good KPS even after failure of multiple prior therapy lines. Here, we explored the combination of carboplatin and etoposide in patients with a third or fourth recurrence of a high-grade glioma. Although only a limited number of patients were examined, our results do not point to clinically relevant activity of such treatment. In contrast, we observed a significant toxicity associated with an impaired quality of life which required hospitalization of some patients.
Platinum-based antineoplastic agents alone or in combination with other drugs have been used for the treatment of gliomas for at least 2 decades [16, 17] . A rather intense regimen, including ifosfamide, carboplatin, and etoposide (ICE), was administered to patients with highgrade glioma at a second or third tumor recurrence [18] . Similarly to our findings, no complete or partial responses were observed. In contrast, promising activity of this regimen was reported in patients with a first tumor recurrence with a 6-month PFS of 35% and a median OS of 10.7 months from the beginning of ICE [19] . Activity was also reported for carboplatin and etoposide in patients with recurrent high-grade glioma after the initial surgical resection followed by RT and no prior chemotherapy with a 6-month PFS of 20% in a phase 1 study including 30 patients [20] .
Our analysis suggests that the activity of carboplatin and etoposide in heavily pretreated patients with highgrade glioma is low, which may be partially explained by the fact that all but one patient had received prior antiangiogenic treatment with bevacizumab which may have precluded benefit from the drugs administered afterwards [21, 22] . Instead, severe toxicity was observed, which may also reflect residual effects of multiple lines of previous therapy in all patients. Similarly to previous studies, we used carboplatin at a dose of 240 mg/m 2 on day 1 [23] . Area under the curve (AUC)-based dosing (Calvert formula) may represent a more suitable way to define the best dose of carboplatin in terms of activity and tolerability. Still, because of its lack of activity and its negative impact on the quality of life, the combination of carboplatin and etoposide cannot be recommended as a routine salvage treatment. Thus, novel treatment approaches for patients with recurrent gliomas are urgently needed and should be the focus of future clinical trials.
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